The A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will include antiretroviral therapy (ART) with acute HIV infection (AHI) to determine whether: Combination therapy with HIV-specific broadly neutralizing antibodies (bNAb) in addition to ART during acute HIV infection (AHI) will be safe. Participants receiving bNAb combination therapy in addition to ART during AHI will be more likely to demonstrate a time delay to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks compared to participants receiving placebo plus ART. Participants receiving bNAb combination therapy in addition to ART during AHI will demonstrate lower viral reservoirs and greater HIV-specific immunity compared to participants receiving placebo plus ART.